Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec;16(6):755-65.
doi: 10.1089/cap.2006.16.755.

Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study

James H Heller  1 , Gail A Spiridigliozzi, Blythe G Crissman, Jennifer A Sullivan, Rebecca L Eells, Jennifer S Li, P Murali Doraiswamy, K Ranga Krishnan, Priya S Kishnani
Affiliations

Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study

James H Heller et al. J Child Adolesc Psychopharmacol. 2006 Dec.

Abstract

Individuals with Down syndrome (DS) exhibit a cholinergic deficiency similar to that found in Alzheimer's disease. Cholinesterase inhibitors, used to treat Alzheimer's disease, may improve cognitive function in individuals with DS. This is the first investigation of the safety and efficacy of rivastigmine (an acetyl and butyryl cholinesterase inhibitor) on specific cognitive domains in pediatric DS. Eleven subjects with DS (ages 10-17 years) were treated with a liquid formulation of rivastigmine. Four subjects experienced no adverse events (AEs). Seven subjects reported AEs that were mild, transient and consistent with adverse events typically noted with cholinesterase inhibitors. Significant improvements were found in overall adaptive function (Vineland Adaptive Behavior Scales and Clinician's Interview-Based Impression of Change), attention (Leiter Attention Sustained tests A and B), memory (NEPSY: Narrative and Immediate Memory for Names subtests) and language (Test of Verbal Expression and Reasoning and Clinical Evaluation of Language Fundamentals-Preschool) domains. Improved language performance was found across all functional levels. These results underscore the need for larger, controlled studies employing a carefully constructed test battery capable of measuring the full scope of performance across multiple domains and a wide range of functional levels.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Study timeline and titration schedule. *Rivastigminc dose increased from 1.5 mg to 3.0 mg at week 2 (dose increase not associated with a study visit).
FIG. 2
FIG. 2
Language treatment effect by subject functional level at Baseline.
See this image and copyright information in PMC

References

    1. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington: University of Vermont, Research Center for Children, Youth, & Families; 2001.
    1. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165–169. - PubMed
    1. Conners CK. Conners’ rating scales-revised, technical manual. North Tonawanda (New York): Multi-Health Systems, Inc.; 1997.
    1. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351:2509–2518. - PubMed
    1. Gardner RJM, Sutherland GR. Chromosome abnormalities and genetic counseling. New York: Oxford University Press; 2004.

Publication types

MeSH terms